Guggenheim Reaffirms Buy on Oruka After Strong ORKA-001 Psoriasis Data

Oruka’s ORKA-001 outperformed Skyrizi on complete clearance in Phase 2b. Analysts model $7B peak sales and maintain bullish ratings.